Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 8—August 2025

Dispatch

Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023

Anna D. BakerComments to Author , Jeremy A.W. Gold, Kaitlin Forsberg, Sophie Jones, and Meghan M. Lyman
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 1

Characteristics of patients with Candida auris screening cases with and without progression to clinical case status, United States, 2016–2023*

Characteristic All, N = 21,195 With clinical case, n = 1,458 Without clinical case, n = 19,737 p value†
Median age at collection of screening case specimen, y (IQR), n = 17,928
68 (58–76)
67 (59–76)
68 (58–77)
0.650
Age group at collection of screening case specimen, y, n = 17,928 0.113
<45 1,738 118 (6.8) 1,620 (93.2)
45–54 1,778 105 (5.9) 1,673 (94.1)
55–64 3,725 279 (7.5) 3,446 (92.5)
65–74 5,239 368 (7.0) 4,871 (93.0)
75–84 3,808 274 (7.2) 3,534 (92.8)
>85
1,640
94 (5.7)
1,546 (94.3)

Sex, n = 16,446 0.478
M 9,448 668 (7.1) 8,780 (92.9)
F
6,998
515 (7.4)
6,483 (92.6)

Antimicrobial Resistance Laboratory Network region of the facility of collection for screening case specimen‡ <0.001
West 6,617 898 (13.6) 5,719 (86.4)
Midwest 4,264 96 (2.3) 4,168 (97.7)
Southeast 4,235 56 (1.3) 4,179 (98.7)
Northeast 3,570 302 (8.5) 3,268 (91.5)
Mid-Atlantic 1,484 64 (4.3) 1,420 (95.7)
Mountain 977 42 (4.3) 935 (95.7)
Central
48
0
48 (100.0)

Facility type of screening case specimen collection, n = 17,357 <0.001
Long-term acute care hospital 8,716 907 (10.4) 7,809 (89.6)
Acute care hospital 5,033 299 (5.9) 4734 (94.1)
Ventilator-equipped skilled nursing facility 2,912 150 (5.2) 2,762 (94.8)
Skilled nursing facility 490 13 (2.7) 477 (97.3)
Other¶ 206 4 (1.9) 202 (98.1)

*Values are no. (%) except as indicated. †p values were calculated using χ2 tests to compare characteristics of patients with a C. auris screening case who had (vs. did not have) progression to a C. auris clinical case. ‡From https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/domestic.html. Data from 2023 were unavailable from 1 state in the Central region. ¶Includes those listed as other (n = 193), inpatient rehabilitation (n = 12), and outpatient (n = 1).

Main Article

Page created: June 16, 2025
Page updated: July 10, 2025
Page reviewed: July 10, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external